Researchers advised that for patients who harbored a high ratio of EGFR mutation in tumor, EGFR-TKI was effective to control the progression of tumor, but for the low, monotherapy of EGFR-TKIs may be not enough. This evidence concerns the gene EGFR and neoplasm.